Your genome is the one document about your health you cannot change — which is exactly why the idea of reading it for longevity is so seductive. Learn your genetic hand, the promise goes, and you can play it optimally. Genetic testing has become cheaper and more available every year, and the marketing has kept pace. But the useful truth is that some genetic information changes real decisions, a great deal of it is fascinating trivia, and telling the two apart is the whole game.
This is a guide to genetic testing for longevity: which tests genuinely alter what you do, which mostly produce interesting numbers, and how to bring any result to your physician in a way that helps rather than alarms.
The categories of genetic testing
“Genetic testing” covers several quite different things, and lumping them together is the source of most confusion.
Single-gene tests for high-impact variants. A minority of people carry specific variants — in genes affecting certain cancers, cardiovascular conditions, or familial cholesterol disorders — that materially change medical management. This is the category where testing can genuinely save lives, and where it is often recommended by physicians, particularly with a suggestive family history. Pharmacogenomics. Testing how your genes affect the way you metabolise certain drugs can be clinically useful in specific situations, informing dosing and choice. Polygenic risk scores. These aggregate the tiny effects of many common variants into a single risk estimate for a condition. They are improving, but for most individuals they shift probabilities modestly rather than delivering verdicts. Consumer ancestry-and-traits kits. Entertaining, occasionally informative, and frequently over-interpreted.
Where genetic testing genuinely earns its place
The clearest case is the high-impact single-gene variant, especially against a family history that already raises suspicion. If a result would change your screening schedule, your preventive options, or your physician’s management, the test is not trivia — it is decision-useful information, and the argument for having it is strong. Pharmacogenomic testing similarly earns its place when you face decisions about specific medications it can inform.
What these have in common is actionability. The result points to a different decision than you would otherwise make. That is the bar, and it is worth applying ruthlessly.
Where it mostly produces trivia
| Test type | Decision-useful? |
|---|---|
| High-impact single-gene variant with family history | Often yes — can change screening and management |
| Pharmacogenomics for a relevant medication decision | Sometimes yes — can inform dosing and choice |
| Polygenic risk score for a common condition | Occasionally — usually shifts probability modestly |
| Consumer traits (“endurance gene,” caffeine metabolism, etc.) | Rarely — interesting, seldom changes action |
The consumer-traits tier is where most enthusiasm and least value coincide. Learning that you carry a variant associated with, say, a particular fitness response is genuinely interesting and almost never changes what a sensible person should do: train, sleep, eat well regardless. A number that cannot move a decision is entertainment, however scientific its packaging.
The considerations before you test
Genetic information has features other tests lack. It is permanent — you cannot un-know it. It implicates your relatives, who share much of your DNA and may not wish to know what you learn. It can carry insurance and privacy implications that vary by jurisdiction. And it can generate anxiety out of proportion to its predictive power, particularly with probabilistic results that many people instinctively read as certainties. None of this argues against testing where it is warranted. It argues for testing deliberately, understanding in advance what you might find and how you would respond.
Genetic and advanced testing navigation is standing work for members: whether a given test is worth it for you, which providers are serious, and how to bring what comes back to your physician usefully — clarity before you spend, translation after. See the extended services on the services page.
Bringing results to your physician
A genetic result is a beginning, not a conclusion, and its value is realised in the conversation that follows. The disciplined path is to understand what a result actually means before you act, to bring genuinely medical findings to a qualified physician — ideally one who works with genetic information — and to resist the temptation to translate a probability into a purchase or a panic. Clarity before you spend, and translation after: that is how genetic testing serves a longevity strategy rather than derailing it.
Used with discipline, genetics can add a genuinely valuable layer to your understanding of your own health. Used as a novelty or a source of dread, it adds cost and worry without changing a single decision. As with everything in this domain, the value is not in the data. It is in knowing which data deserve to change what you do.
Sources
- Green RC, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 2013.
- Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 2018.
- Lewis ACF, Green RC. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Medicine, 2021.
- Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature, 2015.
- Timmers PRHJ, et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases. eLife, 2019.